The Amulet left atrial appendage (LAA) occluder device continued to demonstrate safety and effectiveness through 3 years in the Amulet IDE trial, study lead Dhanunjaya Lakkireddy, MD, reported Saturday at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference in Boston.